Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onconase plus doxorubicin in malignant mesothelioma
NCT00003034Phase 3Unknown
- Sponsor
- Alfacell Corporation
- Start
- May 1997
- Primary completion
- Feb 2008
- Countries
- 4
01
Overview
A Phase 3 trial of ranpirnase in malignant mesothelioma, sponsored by Alfacell Corporation. Status: unknown.
02
Drugs
ranpirnase
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00003034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003034.